Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
NCT05525663
Recruiting
The REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility disability during 6-month follow-up in patients hospitalized for heart failure and preserved ejection fraction (HFpEF), which is nearly unique to older persons, and for which there are few treatment options.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/30/2025
Locations: Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Adaptive Hip Exoskeleton for Stroke Gait Enhancement
NCT05536739
Recruiting
This work will focus on new algorithms for robotic exoskeletons and testing these in human subject tests. Individuals who have previously had a stroke will walk while wearing a robotic exoskeleton on a specialized treadmill as well as during other movement tasks (e.g. over ground, stairs, ramps). The study will compare the performance of the advanced algorithm with not using the device to determine the clinical benefit.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/30/2025
Locations: Exoskeleton and Prosthetic Intelligent Controls Lab, Atlanta, Georgia
Conditions: Stroke
Register for Updates
Pain and Activity Levels After Orthodontic Separators
NCT05615688
Recruiting
The primary aim of this study is to evaluate the reported pain intensity following placement of Orthodontic separators on healthy volunteers aged 15-49 in relation to their recorded physical activity level. Hypothesis 1: The investigators hypothesize that participants with higher daily step counts and physical activity levels will report significantly less pain intensity from orthodontic separators than their less active peers following separator placement. Null hypothesis is that participants... Read More
Gender:
ALL
Ages:
Between 15 years and 49 years
Trial Updated:
06/30/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Dental Malocclusion
Register for Updates
A Study of BLB-201 RSV Vaccine in Infants and Children
NCT05655182
Recruiting
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
06/30/2025
Locations: Paradigm Clinical Research, La Mesa, California +9 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
NCT05656469
Recruiting
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
06/30/2025
Locations: SUNY Upstate Medical University, Department of Psychiatry and Behavioural Sciences, Syracuse, New York +8 locations
Conditions: Mood Disorders, Anxiety Disorders, Psychotic Disorders
Register for Updates
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
NCT05658731
Recruiting
The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients. Patients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and MRI imaging (both research and for regular care) done as p... Read More
Gender:
ALL
Ages:
Between 1 year and 26 years
Trial Updated:
06/30/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia +1 locations
Conditions: Brain Tumor, Head and Neck Cancer
Register for Updates
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
Recruiting
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Mayo Clinic - Phoenix, Phoenix, Arizona +173 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
NCT05713214
Recruiting
Human gene therapy products are designed to achieve therapeutic effect through genetic modifications of human cells using retroviral or lentiviral vectors, resulting in permanent or long-acting changes in the human body. With this genetic modification comes risk of undesirable adverse events. Due to this risk, the Food and Drug Administration (FDA) and the Center for Biologics Evaluation and research (CBER) require long-term follow-up (15 years) of participants that receive investigational gene... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
Register for Updates
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176
Recruiting
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of California San Diego UCSD - Moores Cancer Center, La Jolla, California +58 locations
Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Register for Updates
A Single Arm Pilot Trial of a Social Network Intervention
NCT05745038
Recruiting
The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust \& Adherence or SONATA) is helpful for older individuals receiving cancer treatment. The SONATA program will last for about 4 months. There are a total of 6 coaching sessions. The first 5 sessions will be held approximately every 1 to 2 weeks. Session 6 or the final session will be held approximately 1 to 2 months after session 5. Each session will last for about 1 to 2 hours.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/30/2025
Locations: University of Rochester, Rochester, New York
Conditions: Cancer
Register for Updates
Bone, Exercise, Alendronate, and Caloric Restriction
NCT05764733
Recruiting
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/30/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Bone Loss
Register for Updates
Epcoritamab and Rituximab for First-line Follicular Lymphoma
NCT05783609
Recruiting
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Register for Updates